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Cancer cells have long been known to exhibit metabolic
reprogramming which involves a shift towards glycolysis.
The enhanced glycolysis of cancer cells not only impose
nutrient restriction in the tumor microenvironment, but
also contribute to the acidic environment which is hostile
to the invading anti-tumor immune cells. Hence, targeting
the glycolysis dependency of tumor cells has been
exploited for therapy. The glucose anti-metabolite,
2-deoxyglucose (2DG), a competitive inhibitor of glucose
transport and glucose phosphorylation by hexokinase, has
been extensively tested in various animal models and clini-
cal trials. Although 2DG as anti-cancer agent showed a
limited efficacy, its combined use with other treatment
modalities, including chemotherapy and radiotherapy, has
shown encouraging results. In particular, it has been
shown that the combination of 2DG and cytotoxic agent
etoposide resulted in enhanced antitumor immune
responses, suggesting the therapeutic potential of combin-
ing chemotherapy, immunotherapy and glycolysis inhibi-
tion. We set out to study how metabolic inhibition alters
the tumor microenvironment and how it can be utilized
to augment the efficacy of chemo-immunotherapy.
We found that glycolysis inhibition alone was detrimental
to adoptive T-cell therapy (ACT). However, a rational
combination of chemotherapy, ACT and 2DG led to
tumor eradication and long-term survival in mice. The
underlying mechanism of this synergy will be discussed.
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